vs
Side-by-side financial comparison of WARRIOR MET COAL, INC. (HCC) and Insulet Corporation (PODD). Click either name above to swap in a different company.
Insulet Corporation is the larger business by last-quarter revenue ($761.7M vs $458.6M, roughly 1.7× WARRIOR MET COAL, INC.). WARRIOR MET COAL, INC. runs the higher net margin — 15.8% vs 12.0%, a 3.8% gap on every dollar of revenue. On growth, WARRIOR MET COAL, INC. posted the faster year-over-year revenue change (52.1% vs 33.9%). Over the past eight quarters, Insulet Corporation's revenue compounded faster (24.9% CAGR vs 7.5%).
Warrior Met Coal, Inc. (ticker HCC) is a U.S.-headquartered mining enterprise that produces and distributes high-grade metallurgical coal, a key raw material for steel production. It serves steel manufacturers and industrial clients across core markets including North America, Europe, and Asia.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
HCC vs PODD — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $458.6M | $761.7M |
| Net Profit | $72.3M | $91.1M |
| Gross Margin | 36.7% | 69.5% |
| Operating Margin | 17.3% | 16.0% |
| Net Margin | 15.8% | 12.0% |
| Revenue YoY | 52.1% | 33.9% |
| Net Profit YoY | — | 157.3% |
| EPS (diluted) | $1.37 | $1.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $458.6M | $761.7M | ||
| Q4 25 | $384.0M | $783.7M | ||
| Q3 25 | $328.6M | $706.3M | ||
| Q2 25 | $297.5M | $649.1M | ||
| Q1 25 | $299.9M | $569.0M | ||
| Q4 24 | $297.5M | $597.5M | ||
| Q3 24 | $327.7M | $543.9M | ||
| Q2 24 | $396.5M | $488.5M |
| Q1 26 | $72.3M | $91.1M | ||
| Q4 25 | $23.0M | $101.6M | ||
| Q3 25 | $36.6M | $87.6M | ||
| Q2 25 | $5.6M | $22.5M | ||
| Q1 25 | $-8.2M | $35.4M | ||
| Q4 24 | $1.1M | $100.7M | ||
| Q3 24 | $41.8M | $77.5M | ||
| Q2 24 | $70.7M | $188.6M |
| Q1 26 | 36.7% | 69.5% | ||
| Q4 25 | 29.5% | 72.6% | ||
| Q3 25 | 27.1% | 72.2% | ||
| Q2 25 | 23.9% | 69.7% | ||
| Q1 25 | 18.1% | 71.9% | ||
| Q4 24 | 23.1% | 72.1% | ||
| Q3 24 | 29.3% | 69.3% | ||
| Q2 24 | 34.1% | 67.7% |
| Q1 26 | 17.3% | 16.0% | ||
| Q4 25 | 9.0% | 18.7% | ||
| Q3 25 | 6.3% | 16.7% | ||
| Q2 25 | 2.6% | 18.7% | ||
| Q1 25 | -5.8% | 15.6% | ||
| Q4 24 | -1.4% | 18.3% | ||
| Q3 24 | 11.9% | 16.2% | ||
| Q2 24 | 17.9% | 11.2% |
| Q1 26 | 15.8% | 12.0% | ||
| Q4 25 | 6.0% | 13.0% | ||
| Q3 25 | 11.1% | 12.4% | ||
| Q2 25 | 1.9% | 3.5% | ||
| Q1 25 | -2.7% | 6.2% | ||
| Q4 24 | 0.4% | 16.9% | ||
| Q3 24 | 12.7% | 14.2% | ||
| Q2 24 | 17.8% | 38.6% |
| Q1 26 | $1.37 | $1.30 | ||
| Q4 25 | $0.43 | $1.42 | ||
| Q3 25 | $0.70 | $1.24 | ||
| Q2 25 | $0.11 | $0.32 | ||
| Q1 25 | $-0.16 | $0.50 | ||
| Q4 24 | $0.02 | $1.38 | ||
| Q3 24 | $0.80 | $1.08 | ||
| Q2 24 | $1.35 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $233.2M | $480.4M |
| Total DebtLower is stronger | $154.4M | $18.6M |
| Stockholders' EquityBook value | — | $1.3B |
| Total Assets | $2.8B | $3.0B |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $233.2M | $480.4M | ||
| Q4 25 | $300.0M | — | ||
| Q3 25 | $336.3M | — | ||
| Q2 25 | $383.3M | — | ||
| Q1 25 | $454.9M | — | ||
| Q4 24 | $491.5M | — | ||
| Q3 24 | $583.2M | — | ||
| Q2 24 | $709.0M | — |
| Q1 26 | $154.4M | $18.6M | ||
| Q4 25 | $154.3M | $930.8M | ||
| Q3 25 | $154.1M | $934.9M | ||
| Q2 25 | $153.9M | $939.0M | ||
| Q1 25 | $153.8M | $1.6B | ||
| Q4 24 | $153.6M | $1.3B | ||
| Q3 24 | $153.5M | $1.4B | ||
| Q2 24 | $153.3M | $1.4B |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $2.1B | $1.5B | ||
| Q3 25 | $2.1B | $1.4B | ||
| Q2 25 | $2.1B | $1.5B | ||
| Q1 25 | $2.1B | $1.3B | ||
| Q4 24 | $2.1B | $1.2B | ||
| Q3 24 | $2.1B | $1.1B | ||
| Q2 24 | $2.0B | $998.4M |
| Q1 26 | $2.8B | $3.0B | ||
| Q4 25 | $2.8B | $3.2B | ||
| Q3 25 | $2.7B | $3.0B | ||
| Q2 25 | $2.6B | $3.5B | ||
| Q1 25 | $2.6B | $3.5B | ||
| Q4 24 | $2.6B | $3.1B | ||
| Q3 24 | $2.6B | $3.0B | ||
| Q2 24 | $2.6B | $2.9B |
| Q1 26 | — | 0.01× | ||
| Q4 25 | 0.07× | 0.61× | ||
| Q3 25 | 0.07× | 0.68× | ||
| Q2 25 | 0.07× | 0.64× | ||
| Q1 25 | 0.07× | 1.21× | ||
| Q4 24 | 0.07× | 1.07× | ||
| Q3 24 | 0.07× | 1.21× | ||
| Q2 24 | 0.07× | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $113.8M |
| Free Cash FlowOCF − Capex | — | $89.5M |
| FCF MarginFCF / Revenue | — | 11.8% |
| Capex IntensityCapex / Revenue | — | 3.2% |
| Cash ConversionOCF / Net Profit | — | 1.25× |
| TTM Free Cash FlowTrailing 4 quarters | — | $415.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $113.8M | ||
| Q4 25 | $76.1M | $183.3M | ||
| Q3 25 | $104.7M | $125.7M | ||
| Q2 25 | $37.5M | $196.5M | ||
| Q1 25 | $10.9M | $63.8M | ||
| Q4 24 | $54.2M | $147.7M | ||
| Q3 24 | $62.2M | $98.5M | ||
| Q2 24 | $147.0M | $96.5M |
| Q1 26 | — | $89.5M | ||
| Q4 25 | — | $48.2M | ||
| Q3 25 | — | $100.1M | ||
| Q2 25 | — | $177.9M | ||
| Q1 25 | — | $51.5M | ||
| Q4 24 | — | $94.1M | ||
| Q3 24 | — | $71.8M | ||
| Q2 24 | — | $74.0M |
| Q1 26 | — | 11.8% | ||
| Q4 25 | — | 6.2% | ||
| Q3 25 | — | 14.2% | ||
| Q2 25 | — | 27.4% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | — | 15.7% | ||
| Q3 24 | — | 13.2% | ||
| Q2 24 | — | 15.1% |
| Q1 26 | — | 3.2% | ||
| Q4 25 | — | 17.2% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.0% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | — | 4.6% |
| Q1 26 | — | 1.25× | ||
| Q4 25 | 3.31× | 1.80× | ||
| Q3 25 | 2.86× | 1.43× | ||
| Q2 25 | 6.70× | 8.73× | ||
| Q1 25 | — | 1.80× | ||
| Q4 24 | 47.68× | 1.47× | ||
| Q3 24 | 1.49× | 1.27× | ||
| Q2 24 | 2.08× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HCC
| Sales | $448.5M | 98% |
| Other revenues | $10.1M | 2% |
PODD
| Omnipod | $515.6M | 68% |
| International Omnipod | $242.9M | 32% |
| Drug Delivery | $3.3M | 0% |
